PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.

ABSTRACT: AIM:Programmed death-ligand 1 (PD-L1) has become a widely used predictive biomarker for therapy with checkpoint inhibitors in a variety of cancers. Here, we studied the expression of PD-L1 in squamous cell carcinomas of the vulva (SCCV) with regard to HPV status via its surrogate marker p16. Additionally, the status of PD-L1 and p16 were analyzed for prognostic information and potential correlation to tumor-infiltrating lymphocytes (TILs). METHODS:PD-L1 was analyzed in 128 cases of SCCV using the tumor proportion score (TPS), the immune cell score (ICS) and the combined positive score (CPS). Cases were immunostained for p16 and analyzed for stromal TILs. PD-L1, p16, and TILs were compared to clinico-pathological parameters and patient's survival. RESULTS:TPS ≥ 50% and CPS ≥ 50 were correla

SUBMITTER: Czogalla B 

PROVIDER: S-EPMC7040065 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature